SCHEMBL6902529

SCHEMBL6902529

C1=C(c2ccccn2)c2ccccc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.46
LMNA P02545 3/20 0.46
CCR1 P32246 3/20 0.46
CCR5 P51681 3/20 0.46
CCR8 P51685 3/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
METAP1 P53582 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
DOHH Q9BU89 1/20 0.46
P4HTM Q9NXG6 1/20 0.46
NPC1 O15118 5/20 0.41
TP53 P04637 4/20 0.41
RAB9A P51151 4/20 0.41
ALOX15 P16050 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
HTT P42858 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13400768 0.84 KDM4E (0.42) KDM4ELMNACCR1CCR5CCR8
SCHEMBL27336608 0.74 KDM4E (0.42) KDM4ELMNACCR1CCR5CCR8
SCHEMBL7608467 0.74 HTR6 (0.31)
Fluorene SCHEMBL27950409 0.72 KDM4E (0.61) KDM4ELMNACCR1CCR5CCR8
Fluorene SCHEMBL27530322 0.71 KDM4E (0.52) KDM4ELMNACCR1CCR5CCR8
SCHEMBL858806 0.70 KDM4E (0.72) KDM4ELMNACCR1CCR5CCR8
SCHEMBL170839 0.70 ALDH1A1 (0.39) KDM4ELMNANPC1RAB9ASMN1; SMN2
Dipyridyl SCHEMBL1571842 0.70 KDM4E (0.93) KDM4ELMNACCR1CCR5CCR8
SCHEMBL12853975 0.68 KDM4E (0.68) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29723140 0.68 KDM4E (0.68) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101784529-A Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors HOFFMANN LA ROCHE 2010-07-21 CN claimed
CN-100357326-C Process for preparing aqueous dye-containing polymer dispersions BASF AG (DE) 2007-12-26 CN claimed
CN-1671651-A N-bisaryl- and N-aryl-cycloalkylidenyl-alpha-hydroxy-and alpha-alkoxy acid amides SYNGENTA PARTICIPATIONS AG (CH) 2005-09-21 CN claimed
CN-1520398-A Novel N-isaryl-and N-aryl-cycloalkylidenyl-G(a)-sulfin-and G(a)-sulfonamino acid amides �����ɷ� 2004-08-11 CN claimed
CN-1293680-A Method for producing aqueous polymer dispersions containing colorants BASF AG (DE) 2001-05-02 CN claimed
US-11584726-B2 Amino alcohol derivative, pharmaceutical composition and application thereof BEIJING FORELAND PHARMA CO., LTD. (CN) 2023-02-21 US disclosed
US-20210347745-A1 AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF BEIJING FORELAND PHARMA CO., LTD. (CN) 2021-11-11 US disclosed
EP-3647309-A1 AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Beijing Foreland Pharma Co., Ltd. (CN) 2020-05-06 EP disclosed
CN-102001989-B Heteroarylamine compounds, organic light-emitting devices and panel display devices SAMSUNG MOBILE DISPLAY CO LTD 2014-08-20 CN disclosed
CN-102001987-B Heteroarylamine compound, organic light-emitting device and panel display device SAMSUNG SDI CO LTD 2013-05-22 CN disclosed
CN-102448958-A Pyrimidinyl and 1,3, 5-triazinyl benzimidazole sulfonamides and their use in the treatment of cancer PATHWAY THERAPEUTICS LTD 2012-05-09 CN disclosed
CN-101360745-B 8-azabicyclo[3.2.1]octane derivatives useful as monoamine reuptake inhibitors N.V. ORGANON (NL) 2011-12-14 CN disclosed
CN-1520398-A Novel N-isaryl-and N-aryl-cycloalkylidenyl-G(a)-sulfin-and G(a)-sulfonamino acid amides �����ɷ� 2004-08-11 CN disclosed
EP-1033371-B1 Transition metal compound, catalyst system, process for the preparation thereof and its use for the polymerization of olefins BASELL POLYOLEFINE GMBH (DE) 2004-01-28 EP disclosed
US-6458982-B1 CATALYST SYSTEM COMPRISING AT LEAST ONE METALLOCENE AND AT LEAST ONE COCATALYST. ON SUPPORT. TARGOR GMBH (DE) 2002-10-01 US disclosed
CN-1308606-A Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMACEUTICALS AG (DE) 2001-08-15 CN disclosed
CN-1293680-A Method for producing aqueous polymer dispersions containing colorants BASF AG (DE) 2001-05-02 CN disclosed
EP-1033371-A1 Transition metal compound, catalyst system, process for the preparation thereof and its use for the polymerization of olefins TARGOR GmbH (DE) 2000-09-06 EP disclosed
CN-1145075-A Antagonist's of endothelin receptors JAPAT LTD (CH) 1997-03-12 CN disclosed
CN-1087781-A Plant growth regulator UNION OIL CO (US) 1994-06-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210347745-A1 AMINO ALCOHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SSB, HLA-DRB1, LCP2 KDM4E 1161/4885LMNA 438/4885CCR1 374/4885
US-11584726-B2 Amino alcohol derivative, pharmaceutical composition and application thereof SSB, HLA-DRB1, LCP2 KDM4E 1161/4885LMNA 438/4885CCR1 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.